Genomictree Inc. (228760)
KRX SM KRX SM Primary Summary
Genomictree Inc. (228760) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Genomictree Inc. ever had a stock split?
Genomictree Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Sung-Whan An CEO | KRX SM Exchange | KR7228760005 ISIN |
| KR Country | 77 Employees | - Last Dividend | 14 Sep 2018 Last Split | - IPO Date |
Overview
Genomictree Inc. is a pioneer in the field of biomarker-based molecular diagnostics, focusing on the development and commercialization of cutting-edge molecular diagnostic products designed for the early detection of cancer and various infectious diseases. Founded in the year 2000 and having its headquarters in Daejeon, South Korea, Genomictree Inc. stands at the forefront of healthcare innovation, dedicated to improving early cancer detection rates and the management of infectious diseases through advanced diagnostic solutions.
Products and Services
Genomictree Inc. offers an array of molecular diagnostic products, each tailored for the detection of specific diseases, leveraging both genetic and epigenetic markers. These products exemplify the company's commitment to enhancing patient outcomes through early diagnosis.
- EarlyTect C: A revolutionary screening method for the early diagnosis of colorectal cancer. It utilizes advanced molecular diagnostic techniques to identify cancer at its nascent stage, aiming to drastically improve treatment outcomes and survival rates.
- EarlyTect L: This diagnostic tool is designed for the detection of epigenetic markers associated with lung cancer, particularly in patients with pulmonary nodules. EarlyTect L provides a non-invasive approach to identifying potential lung cancer at an early stage, facilitating prompt and targeted treatment interventions.
- EarlyTect B: Tailored for hematuria patients, this product focuses on the detection of genetic and epigenetic markers associated with bladder cancer. EarlyTect B represents a significant advancement in bladder cancer diagnostics, offering hope for early intervention and improved patient prognoses.
- AccuraDTect SARS-CoV-2 RT-qPCR Kit: In response to the global pandemic, Genomictree Inc. has developed this kit for the in vitro qualitative detection of SARS-CoV-2 RNA. It is designed for use with nasopharyngeal or oropharyngeal swabs, test providers, and nucleic acid transport medium, contributing to the global efforts in managing and controlling the spread of COVID-19.
